Boston Scientific Scimed, Inc.

Varian Medical Systems, Inc.

Hongxia Zeng

Yen-Lane Chen

Hong Cao

Steven L Kangas

Dongming Hou

Jonathan Pascal Chaky

Bryan Allen Clark

Tim O'Connor

Bruce R Forsyth

Heidi Schwanz

Raghav Goel

Ming Dang

Matthew R DeWitt

A radiopaque anchor and delivery device system may comprise a pigtail catheter and a radiopaque anchor. The pigtail catheter may be a dual lumen catheter configured to deploy the radiopaque anchor and delivery a radiopaque fluid or contrast agent. The implantable radiopaque anchor may be slidably disposed within and deployable from a lumen of the elongate shaft. A method for deploying an implantable radiopaque anchor may include advancing a pigtail catheter through the vasculature to a target location; identifying an implant location; forming a channel in a tissue at the implant location; and deploying an implantable radiopaque anchor within the channel.

Radiopaque marker and delivery system

In one aspect, the present disclosure pertains to elutable coating compositions that comprise an excipient comprising a bio-degradable or bio-stable polymer selected from a poly(lactic-co-glycolic acid) (PLGA) or methyl cellulose (MCC), a binding agent; a therapeutic agent. In some embodiments, the elutable coating compositions further comprise a solvent, in which case such compositions may be, for example, applied to a substrate in the form of a layer and subsequently dried, thereby forming an elutable coating on the substrate.

Drug release coating compositions

Polymer microspheres for embolizing blood vessels and optionally delivering therapeutic agents are provided.

Biodegradable drug eluting microsphere for the treatment of solid tumors

Methods are disclosed including methods for crystallizing a material such as a drug. An example method may include combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension. The method may also include incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form.

Methods for crystallization of drugs

An occlusive implant includes an expandable framework that is configured to shift between a collapsed configuration and an expanded configuration. An occlusive member is disposed along at least a portion of the expandable framework. At least part of the occlusive implant is configured to repel fibrinogen. In some cases, the occlusive implant may be configured for placement within a left atrial appendage (LAA) of a patient's heart.

Occlusive medical device with charged polymer coating

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.

Embolic microspheres

Polymer microspheres for embolizing blood vessels and optionally delivering therapeutic agents are provided. The microspheres include PLGA 50:50 and/or Ptx, and are generally formed by emulsion means.

Growing community of inventors

Maple Grove, MN, United States of America

Hongxia Zeng